Drug profile · INN
arcitumomab
CEA-SCAN
arcitumomab (CEA-SCAN) is a carcinoembryonic antigen-related cell adhesion molecule 5 binding agent.
EMA: withdrawn Various (V09) V09IA01
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — arcitumomab
- Class
- Various (V09)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
arcitumomab (CEA-SCAN) is a carcinoembryonic antigen-related cell adhesion molecule 5 binding agent.
Key facts
INN arcitumomab
Brand CEA-SCAN
Mechanism Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent
Target Cell adhesion molecule CEACAM5
Therapeutic class Various (V09)
ATC code V09IA01
Mechanism of action
Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent
Primary target: Cell adhesion molecule CEACAM5
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | withdrawn | — |
Related & competitor drugs
Frequently asked questions
What is arcitumomab?
arcitumomab (CEA-SCAN) is a carcinoembryonic antigen-related cell adhesion molecule 5 binding agent.
What is the brand name for arcitumomab?
CEA-SCAN is a marketed brand name for arcitumomab. Check FDA Drugs@FDA for the current US label holder and prescribing information.